Man Group PLC Bio Atla, Inc. Transaction History

Man Group PLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	SELL	$2.83 - $3.87 $146,211 - $199,943	-51,665 Reduced 57.89%	37,588 $112,000
Q1 2023 May 15, 2023	BUY	$2.3 - $8.25 $171,752 - $616,068	74,675 Added 512.24%	89,253 $239,000
Q4 2022 Feb 14, 2023	BUY	$6.29 - $11.01 $18,285 - $32,006	2,907 Added 24.91%	14,578 $120,000
Q3 2022 Nov 14, 2022	SELL	$2.94 - $11.87 $27,133 - $109,548	-9,229 Reduced 44.16%	11,671 $90,000
Q2 2022 Aug 15, 2022	BUY	$2.13 - $5.38 $16,827 - $42,502	7,900 Added 60.77%	20,900 $60,000
Q1 2022 May 16, 2022	BUY	$4.38 - $18.78 $56,940 - $244,140	13,000 New	13,000 $65,000

22.1M

10.7K

7.4K

Ticker BCAB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 36,304,100
Market Cap $59.2M
Description
BioAtla, Inc., a clinical stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead product candidate is BA3011, a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for soft tissue and bone sarcoma tumors, non-small cell lung cancer (NSCLC), and ...

Get notified when there are updates to the investment portfolio of Man Group PLC, based on Form 13F filings with the SEC.

Stay updated on Man Group PLC with notifications on news.